Close Menu

Weizmann Institute

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.

Overexpression of immunoproteasome components PSMB8 and PSMB9 were found to be predictive of improved survival and response to immunotherapy.